<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04274426</url>
  </required_header>
  <id_info>
    <org_study_id>AGO-OVAR 2.34</org_study_id>
    <secondary_id>2018-004207-39</secondary_id>
    <nct_id>NCT04274426</nct_id>
  </id_info>
  <brief_title>Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer</brief_title>
  <acronym>MIROVA</acronym>
  <official_title>A Randomized Phase II Trial of Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer Eligible for Platinum-based Chemotherapy. Supported by: DIAGNOSTIC PROTOCOL for the VENTANA FOLR1 (FOLR1-2.1) CDx Assay Ventana No. RD004881; Protocol Document No. D152967</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGO Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGO Research GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, two-arm, open-label, comparative phase II trial of&#xD;
      Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian&#xD;
      cancer eligible for platinum-based chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      136 patients will be randomized into the follow-ing two treatment arms as specified below:&#xD;
&#xD;
      Arm A: Control arm Platinum-based chemotherapy Arm B: Carboplatin + Mirvetuximab soravtansine&#xD;
      (IMGN853)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS) defined as the time from randomization to progressive disease (PD) or death, whichever occurs earlier. PD is based on investigator assess-ment using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).</measure>
    <time_frame>Up to 2.5 years. From date of randomization until date of progressive disease (PD) or death, whichever occurs earlier.</time_frame>
    <description>PD is based on investigator assessment using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Up to 2.5 years. From date of randomization until date of death from any cause.</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Up to 2.5 years. From date of randomization to date of death death from any cause.</time_frame>
    <description>Objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy regarding PFS</measure>
    <time_frame>Up to 2.5 years. From date of randomization to date of death from any cause.</time_frame>
    <description>Efficacy regarding Progression Free Survival depending on histologic subtype</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy regarding OS</measure>
    <time_frame>Up to 2.5 years. From date of randomization to date of death from any cause.</time_frame>
    <description>Efficacy regarding Overall Survival depending on histologic subtype</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy regarding ORR</measure>
    <time_frame>Up to 2.5 years. From date of randomization to date of death from any cause.</time_frame>
    <description>Efficacy regarding Objective Response Rate depending on histologic subtype</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serological progressive disease</measure>
    <time_frame>Up to 2.5 years. From date of randomization to date of death death from any cause.</time_frame>
    <description>Time to serological progressive disease according to GCIG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first subsequent treatment (TFST)</measure>
    <time_frame>Up to 2.5 years. From date of randomization to date of death from any cause.</time_frame>
    <description>Time to first subsequent treatment (TFST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to second subsequent treatment (TSST)</measure>
    <time_frame>Up to 2.5 years. From date of randomization until date of death from any cause.</time_frame>
    <description>Time to second subsequent treatment (TSST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes</measure>
    <time_frame>Up to 2.5 years. From date of randomization until date of death from any cause.</time_frame>
    <description>Quality of Life (EORTC C-30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes</measure>
    <time_frame>Up to 2.5 years. From date of randomization until date of death from any cause.</time_frame>
    <description>Quality of Life (EORTC OV28)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 2.5 years. From date of randomization until date of death from any cause through study completion.</time_frame>
    <description>Safety and tolerability of the used drugs evaluated by NCI CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Control arm with Platinum-based chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carboplatin (AUC5, d1) combined with pegylated liposomal doxorubicin (PLD) (30 mg/m², d1) q28d&#xD;
Carboplatin (AUC4, d1) combined with gemcitabine (1000 mg/m2, d1 &amp; d8) q21d&#xD;
Carboplatin (AUC5, d1) combined with paclitaxel (175 mg/m², d1) q21d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carboplatin + Mirvetuximab soravtansine (IMGN853)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin (AUC5, d1) + Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV d1 x 6 cycles q21d, followed by subsequent monotherapy of Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV q3w until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin will administered by intravenous route</description>
    <arm_group_label>Carboplatin + Mirvetuximab soravtansine (IMGN853)</arm_group_label>
    <arm_group_label>Control arm with Platinum-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated liposomal doxorubicin (PLD)</intervention_name>
    <description>PLD will be administered by intravenous route</description>
    <arm_group_label>Control arm with Platinum-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine will be administered by intravenous route</description>
    <arm_group_label>Control arm with Platinum-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel will be administered by intravenous route</description>
    <arm_group_label>Control arm with Platinum-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirvetuximab Soravtansine</intervention_name>
    <description>Mirvetuximab Soravtansine will be administered by intravenous route</description>
    <arm_group_label>Carboplatin + Mirvetuximab soravtansine (IMGN853)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All patients must have a pathologically documented, definite diagnosis of epithelial&#xD;
             cancer of the ovary, the fallopian tube or the peritoneum&#xD;
&#xD;
          2. Relapsed disease with a platinum-free interval &gt;3 months&#xD;
&#xD;
          3. All histologic subtypes of ovarian carcinoma including carcinosarcoma (malignant mixed&#xD;
             Mullerian tumors, MMMT)&#xD;
&#xD;
          4. Patients with wildtype BRCA1/2 mutation status or with a deleterious BRCA1/2 mutation&#xD;
             in germline or somatic testing if they underwent PARP inhibitor therapy in previous&#xD;
             treatment line.&#xD;
&#xD;
          5. Patients must be willing to provide archival tumor tissue from current relapse or&#xD;
             previous surgeries/biopsies for central confirmation of FRα high status by PS2+&#xD;
             scoring:&#xD;
&#xD;
             all tumors must exhibit ≥75% of tumor cells with FRα membrane staining and ≥ 2+&#xD;
             intensity by immunohistochemistry (IHC) using the Ventana FOLR1 (FOLR1 2.1) CDx assay.&#xD;
&#xD;
          6. Patients must have measurable disease or evaluable disease in combination with GCIG&#xD;
             CA-125 criteria.&#xD;
&#xD;
          7. Patients had one or more prior lines of chemotherapy. The last line of chemotherapy&#xD;
             should have included platinum and has resulted in a partial or complete response.&#xD;
&#xD;
          8. Major surgery (not including placement of vascular access device, tumor punch/scrape&#xD;
             biopsies or secondary wound closure) must be completed four weeks prior to Day 1.&#xD;
&#xD;
          9. Patients must have adequate hematological, liver, cardiac and kidney function:&#xD;
&#xD;
               1. Hemoglobin ≥ 10.0 g/dL.&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
               3. Platelet count ≥ 100 x 109/L.&#xD;
&#xD;
               4. Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN).&#xD;
&#xD;
               5. Aspartate aminotransferase/Serum Glutamic Oxaloacetic Transaminase (ASAT/SGOT))&#xD;
                  and Alanine aminotransferase/Serum Glutamic Pyruvate Transaminase (ALAT/SGPT)) ≤&#xD;
                  2.5 x ULN, unless liver metastases are present in which case they must be ≤ 5 x&#xD;
                  ULN.&#xD;
&#xD;
               6. Serum creatinine ≤ 1.5 x institutional ULN and glomerular filtration rate of at&#xD;
                  least 40 ml/minute according to Cockroft-Gault formula.&#xD;
&#xD;
         10. Patient is female and ≥18 years of age at the time of the first screening visit.&#xD;
&#xD;
         11. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.&#xD;
&#xD;
         12. Patients must be willing and able to sign the informed consent form, and to adhere to&#xD;
             the study visit schedule and other protocol requirements.&#xD;
&#xD;
         13. Women of childbearing potential (a woman is considered of childbearing potential&#xD;
             (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless&#xD;
             permanently ster-ile. Permanent sterilization methods include hysterectomy, bi-lateral&#xD;
             salpingectomy and bilateral oophorectomy) must have a negative serum pregnancy test&#xD;
             within 3 days from day 1 of cycle 1 and agree to use a highly effective method of&#xD;
             contraception while on study treatment and for at least 6 months after end of&#xD;
             treatment. Such methods include:&#xD;
&#xD;
               1. Combined (estrogen and progestogen containing) hor-monal contraception associated&#xD;
                  with inhibition of ovulation:&#xD;
&#xD;
                    -  oral&#xD;
&#xD;
                    -  intravaginal&#xD;
&#xD;
                    -  transdermal&#xD;
&#xD;
               2. Progestogen-only hormonal contraception associated with inhibition of ovulation:&#xD;
&#xD;
                    -  oral&#xD;
&#xD;
                    -  injectable&#xD;
&#xD;
                    -  implantable&#xD;
&#xD;
               3. Intrauterine device (IUD)&#xD;
&#xD;
               4. Intrauterine hormone-releasing system ( IUS)&#xD;
&#xD;
               5. Bilateral tubal occlusion&#xD;
&#xD;
               6. Vasectomized partner&#xD;
&#xD;
               7. Sexual abstinence&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-epithelial tumor origin of the ovary, the fallopian tube or the peritoneum (i.e.&#xD;
             germ cell tumors)&#xD;
&#xD;
          2. Ovarian tumors of low malignant potential (e.g. borderline tumors).&#xD;
&#xD;
          3. Unknown BRCA status.&#xD;
&#xD;
          4. Patients who are planned to receive bevacizumab for the current relapse.&#xD;
&#xD;
          5. Other malignancy within the last 3 years (except cervix or breast in situ carcinoma,&#xD;
             type I stage I endometrial cancer)&#xD;
&#xD;
          6. Patients who underwent surgery for the current relapse with macroscopic complete&#xD;
             resection&#xD;
&#xD;
          7. Prior systemic anticancer therapy within 28 days before randomization&#xD;
&#xD;
          8. Prior treatment with folate receptor-targeting investigational agents is not allowed.&#xD;
&#xD;
          9. Patients with &gt; Grade 1 peripheral neuropathy.&#xD;
&#xD;
         10. Serious concurrent illness or clinically-relevant active infection&#xD;
&#xD;
         11. Previous clinical diagnosis of non-infectious interstitial lung disease, including&#xD;
             non-infectious pneumonitis.&#xD;
&#xD;
         12. Active or chronic corneal disorders such as Sjogren's syndrome, Fuchs corneal&#xD;
             dystrophy (requiring treatment), history of corneal transplantation, active herpetic&#xD;
             keratitis, active ocular conditions requiring ongoing treatment/monitoring such as&#xD;
             uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal&#xD;
             injections, active diabetic retinopathy with macular edema, macular degeneration,&#xD;
             presence of papilledema, and /or monocular vision. Active or chronic corneal disorder&#xD;
&#xD;
         13. Required use of folate-containing supplements (e.g. folate deficiency)&#xD;
&#xD;
         14. Women of childbearing potential (WOCBP) not protected by highly effective&#xD;
             contraceptive methods.&#xD;
&#xD;
         15. Pregnant and/or breast-feeding women.&#xD;
&#xD;
         16. Known hypersensitivity to one of the chemotherapy re-gimes and/or PARP inhibitors&#xD;
             and/or any of their excipients.&#xD;
&#xD;
         17. Patients with prior hypersensitivity to monoclonal antibodies.&#xD;
&#xD;
         18. Patients with potential risks according to contraindication, warnings or interactions&#xD;
             of the used chemotherapeutic agents as stated in the SmPCs are not eligible for&#xD;
             partici-pation in this trial.&#xD;
&#xD;
         19. Patients with untreated or symptomatic central nervous system (CNS) metastases&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Harter</last_name>
    <role>Study Chair</role>
    <affiliation>Kliniken Essen-Mitte, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michaela Fredrich</last_name>
    <phone>+49 611 880467</phone>
    <phone_ext>42</phone_ext>
    <email>mfredrich@ago-ovar.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charite Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jalid Sehouli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eva-Katharina Egger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtische Klinikum Dessau</name>
      <address>
        <city>Dessau</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Ganser</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl-Gustav-Carus an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pauline Wimberger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tanja Fehm</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelische Kliniken-Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Harter</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ahmed El.Balat</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara Schmalfeldt, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tjoung-Won Park-Simon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ViDia Christliche Kliniken Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oliver Tome, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriele Feisel-Schwickardi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Krefeld</name>
      <address>
        <city>Krefeld</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gunther Rogmans</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth-Krankenhaus GmbH</name>
      <address>
        <city>Köln-Hohenlind</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Rein</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Kalder</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabian Trillsch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rotkreuzklinikum München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Poelcher</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>TU München, Klinikum recht der Isar</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Holger Bronger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralf Witteler</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Südstadt Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian George, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabienne Schochter</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ago-ovar.de/</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Maytansine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

